At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia. A Randomized, Placebo-controlled, Double Blind Investigation.
In Brief
A clinical study evaluating Potassium citrate, Placebo, and 2 other interventions for Osteopenia and Bone Disease, Metabolic. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate whether the use of alkali compounds, i.e. potassium citrate (K3C6H5O7, hereinafter KCitr) is effective in preventing the progression of osteopenia. A randomized clinical trial (RCT, placebo-controlled, double-blind) has been planned to evaluate the effect of the daily administration of KCitr (3 g/die, K 30 mEq). The efficacy will be evaluated by comparing the circulating levels of bone turnover markers at the baseline and after the treatment (3, 6 months).
Study Details
Timeline
Interventions
Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
400 IU/die Vitamin D3 daily by mouth
500 mg/die calcium carbonate daily by mouth